SPIRIVA HANDIHALER
LAMA DPI
Tiotropium bromide · Boehringer Ingelheim
Active Medication & Mechanism
- Tiotropium bromide monohydrate LAMA18 mcg per capsule (delivers a mean of 10.4 mcg from the mouthpiece in vitro at 39 L/min)
Long-acting muscarinic antagonist (anticholinergic). Binds to M1–M3 muscarinic receptors, with slow dissociation from M3 receptors on airway smooth muscle, providing 24-hour bronchodilation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
18 mcg
2 inhalations of 1 capsule once daily (entire capsule content) → 18 mcg
FDA Approved
Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.
Not Approved
Spiriva HandiHaler is NOT indicated for asthma. Use Spiriva Respimat for asthma (different product and dose).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
18 mcg 2 inhalations of 1 capsule once daily (entire capsule content) → 18 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.
Asthma Not Approved
Spiriva HandiHaler is NOT indicated for asthma. Use Spiriva Respimat for asthma (different product and dose).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Use a SABA.
Related Inhalers
Same active ingredients (Tiotropium)